IMPACT BIOMEDICAL Business Summary

Impact BioMedical Inc. (IBO) operates as a biotechnology research and development firm utilizing a dual revenue model centered on the licensing of its proprietary intellectual property and the direct commercialization of wellness products. The company’s primary business segments focus on specialty biopharmaceuticals, antivirals, and antimicrobials, supported by key technology platforms such as Linebacker™ (small molecule polyphenols for oncology and neurology), Equivir™ (antiviral blends), and Laetose™ (a functional sugar-inositol combination). As of March 2026, IBO is in the final stages of a strategic merger with Dr Ashleys Limited, a move intended to scale its manufacturing and global distribution capabilities. Within the competitive landscape, IBO contends with micro-cap biopharmaceutical peers such as Incannex Healthcare, Veru Inc., and Daré Bioscience; it distinguishes itself through a lean, IP-heavy operational structure that prioritizes patent acquisition over capital-intensive in-house clinical infrastructure. The leadership team is spearheaded by Chairman and CEO Frank D. Heuszel, a legal and financial veteran with a J.D. from South Texas College of Law and extensive experience in commercial banking and strategic planning. He is supported by Chief Operating Officer Mark Suseck, who brings a pedigree in healthcare commercialization and licensing from his previous roles at Vivacitas Oncology and DSS BioHealth Holdings, and Chief Financial Officer Todd Macko, who possesses over 25 years of expertise in business process engineering and M&A. The company is a subsidiary of DSS, Inc., which remains its primary institutional backer and majority shareholder, holding approximately 88.87% of the company’s shares. The Board of Directors includes notable figures such as Chan Heng Fai Ambrose, a seasoned international investor and Chairman of DSS, Inc., and Jason Grady, ensuring strong alignment with its parent organization’s diversified global strategy.